Belgium-Based JLINX Incubator to Transition to Johnson & Johnson Innovation JLABS, Expanding Outreach Across Europe
The Belgium-based JLINX incubator – a collaboration launched in March 2016 between Janssen Pharmaceutica NV and Bioqube Ventures – will become part of the global Johnson & Johnson Innovation network, transitioning into a JLABS, making this the first JLABS in Europe and the 10th JLABS in the world. Called JLABS @ BE, the site will accommodate up to 30 life science startups focused on innovations across the entire healthcare spectrum, including biotech, pharmaceuticals, medical devices, consumer and healthtech sectors.
JLABS @ BE will be located at the heart of the Beerse Janssen R&D Campus where Dr. Paul Janssen – one of the 20th century’s most innovative and productive pharmaceutical researchers – first established Janssen Pharmaceutica NV more than six decades ago, laying the foundation for the discovery and development of more than 80 new medicines during his lifetime.
“By creating a JLABS on the Beerse Janssen R&D Campus, we take another step towards our vision of a truly global, open innovation ecosystem. This unique model will support entrepreneurs in progressing their transformative science through access to state-of-the-art infrastructure, expertise and funding opportunities and all in the knowledge that their ideas can progress with no-strings attached,” said Melinda Richter, Global Head of JLABS, Johnson & Johnson Innovation. “We are proud of our commitment to nurture breakthrough science regardless of where it originates with the ambition of solving the greatest unmet medical and healthcare needs of our time.”
JLABS @ BE will provide resident entrepreneurs with a capital efficient and flexible platform, including an extensive global network, that will enable them to accelerate the delivery of life-saving, life-enhancing health and wellness solutions to consumers and patients both in Europe and around the world.
“We are inspired by Dr. Paul Janssen’s famous call-to-action, The patients are waiting,” said Bill Hait, Global Head, Global External Innovation, Johnson & Johnson. “Our goal is to attract the best and brightest talent in science and technology, and to work with partners in healthcare to help start new, highly innovative companies, providing a wealth of incubation options for our partners and insights to new innovation for our businesses around the globe.”
Today’s launch of JLABS @ BE demonstrates Johnson & Johnson Innovation’s continued commitment to enabling the best science and technology regardless of origin with the ambition of solving the greatest unmet medical and healthcare needs of our time. JLABS @ BE will follow the successful no-strings attached JLABS model that has been host to over 330 companies that have collectively raised over $9.4B in growth capital. JLABS @ BE will provide startups with many of the advantages of being part of an established innovation hub, such as access to talent and mentors, large existing firms and research universities, capital and convergence opportunities with other sectors.
“We are confident that JLABS will build upon the vibrant base in Beerse and the foundational roots of JLINX, that were established in partnership with the Bioqube Ventures team, as well as further connect the region to a growing global network of JLABS ecosystems teeming with startups and entrepreneurs. We are proud to make this ecosystem part of Dr. Paul Janssen’s namesake campus,” says Stef Heylen, Chief Operating Officer, Development, Janssen R&D and Managing Director, Janssen Pharmaceutica NV Belgium.
Startups and entrepreneurs from biotech, pharmaceutical, medical device, consumer and healthtech companies interested in applying to join the JLABS @ BE community can reach out by visiting jlabs.jnjinnovation.com.
JLABS @ BE will continue to benefit from 2.1 million euros of financial support granted by the European Regional Development Fund (ERDF) and the government agency Flanders Innovation & Entrepreneurship (VLAIO – Hermesfonds) in 2017.
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people with serious diseases throughout the world. Beyond its innovative medicines, Janssen is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care.
Janssen Pharmaceutica NV, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit www.janssen.com for more information. Follow us on Twitter at @JanssenGlobal.
Vice President of Innovation, Global Health and Policy Communication
+ 1 908 405 1144
Innovation Communication Leader, London
+44 (0) 7767 310 550
Johnson & Johnson
Vice President, Global Media Relations
+1 917 697 2318
Head, EMEA Media
+44 7879 866200
Senior Director Investor Relations
+1 908 652 1899
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IWBI Announces First WELL Portfolio Participants25.9.2018 18:00 | Pressemelding
The International WELL Building Institute™ (IWBI™) announced today the first participants in WELL Portfolio™, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio. Being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™), it is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets. The announcement quickly follows the launch of WELL v2, the second iteration of IWBI’s pioneering WELL Building Standard. The addition of an early phase review process enabling projects to seek the WELL D&O™ designation, introduced in WELL v2, allows portfolio projects to move through the certification process in a more streamlined and systematic fashion across their asset base, with a specific focus on polici
Mobile Industry Accelerating Delivery of Sustainable Development Goals, According to Latest GSMA Report25.9.2018 17:00 | Pressemelding
The global mobile industry is demonstrating significant and measurable impact in contributing to the UN’s Sustainable Development Goals (SDGs) and is strengthening its commitment to improving lives around the world, according to a new GSMA study. The 2018 edition of the GSMA’s annual ‘Mobile Industry Impact’ report, published at the UN General Assembly this week, found that the industry has continued to increase its contribution against all 17 Goals since mobile become the first sector in the world to commit to delivery of the SDGs in 2016. This growing impact reflects mobile’s unprecedented global scale, which provides a platform to connect unconnected communities, reduce poverty, improve access to healthcare and education, and drive sustainable economic growth. “More than two-thirds of the people on the planet are now connected to a mobile network and, for many, mobile is the primary – sometimes only – channel for accessing the internet and life-enhancing services,” commented Mats Gr
PMI: Taking Bold Action for Global Change: a Conversation on Tobacco Today and Transformation for Tomorrow25.9.2018 15:43 | Pressemelding
During the 2018 Concordia Annual Summit, taking place in September 24 & 25 in New York, André Calantzopoulos, CEO of Philip Morris International, delivered a speech highlighting the need to have a dialogue between the industry, leaders, policy-makers, scientists, medical, and public health professionals in order to provide the 1.1 billion people who smoke with better alternatives to cigarettes. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact. The remarks by André Calantzopoulos follow: “I'm the Chief Executive Officer of a tobacco company. I’m here today because, as global leaders come together in New York for the United Nations General Assembly, this is the time and place to discuss today's problems and their potential solutions. “Smoking tobacco is a behavioral risk factor
ExaGrid Achieves a Net Promoter Score of +7325.9.2018 15:22 | Pressemelding
ExaGrid ®, a leading provider of hyper-converged secondary storage for backup, today announced that the company has achieved a Net Promoter Score (NPS) of +73 in response to a recently conducted NPS survey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005883/en/ The NPS customer loyalty metric measures how likely existing customers are to recommend a vendor’s product or service to a colleague. The resulting NPS score can be as low as -100 or as high as +100. Most of ExaGrid’s competitors have an NPS of between +10 and +20 versus ExaGrid at +73. We attribute the satisfaction of our customers to our unique product architecture, the fact that the product “just works,” and also to a unique support model: Each customer is assigned to a senior level 2 support tech. Customers consistently deal with the same support tech who virtually becomes an extension of the customer’s IT team; the tech knows the customer, their environm
Abu Dhabi International Hunting and Equestrian Exhibition 2018 Opens its Doors Today25.9.2018 15:17 | Pressemelding
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region, Chairman of the Emirates Falconers’ Club, the 16th Edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) was inaugurated at Abu Dhabi National Exhibition Center (ADNEC), which will run until 29th September, and celebrates this year the centennial of the late Sheikh Zayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005875/en/ Scenes from ADIHEX - (Photo: AETOSWire) The event is organized by the Emirates Falconers’ Club and is supported by the Environment Agency - Abu Dhabi (EAD), International Fund for Houbara Conservation (IFHC), the Department of Culture and Tourism (DCT) and The Cultural Programs and Heritage Festivals Committee in addition to many local, regional and international media partners. The main sponsor is His Highness Sheikh Mansoor bin Zayed Al Nahyan Global A
Andersen Global Welcomes Tufiño & Villegas in Bolivia25.9.2018 13:30 | Pressemelding
Andersen Global continues its growth in Latin America with news that one of the premier tax law firms in Bolivia, Estudio Jurídico Tufiño Villegas & Asoc., has become a collaborating firm of Andersen Global. Tufiño & Villegas specializes in providing legal services to both local and foreign corporations that do business in Bolivia. With offices in La Paz, Santa Cruz and Cochabamba, the signing of a Collaboration Agreement with Tufiño & Villegas kickstarts Andersen Global’s presence in the South American country. The international organization has almost doubled its headcount in Latin America in the past eight months. Through its member firms and collaborating firms, Andersen Global already has a strong presence in the region in several major economic hubs – Mexico, Guatemala, Panama, Chile, Uruguay, Ecuador, Brazil, and most recently Paraguay. Led by Founders and Managing Partners Alvaro Villegas Aldazosa and Jose Luis Tufiño, the firm, Tufiño & Villegas, was created in 1995 as a tax b